Brokerages Set Gain Therapeutics, Inc. (NASDAQ:GANX) Target Price at $7.50

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have been given an average recommendation of “Moderate Buy” by the six brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $7.50.

A number of brokerages recently weighed in on GANX. Wall Street Zen upgraded shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, June 21st. Oppenheimer reiterated an “outperform” rating on shares of Gain Therapeutics in a report on Wednesday, May 27th. BTIG Research reissued a “buy” rating and issued a $5.00 price target on shares of Gain Therapeutics in a research report on Tuesday, August 11th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a research note on Monday, August 31st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Friday, September 4th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its stake in shares of Gain Therapeutics by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after buying an additional 8,251 shares during the period. Marshall Wace LLP increased its stake in shares of Gain Therapeutics by 41.0% during the second quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock worth $498,000 after buying an additional 80,407 shares during the period. JPMorgan Chase & Co. acquired a new stake in Gain Therapeutics in the third quarter valued at approximately $47,000. Squarepoint Ops LLC acquired a new stake in Gain Therapeutics in the third quarter valued at approximately $68,000. Finally, Virtu Financial LLC lifted its stake in Gain Therapeutics by 126.9% in the third quarter. Virtu Financial LLC now owns 54,008 shares of the company’s stock worth $96,000 after acquiring an additional 30,207 shares during the last quarter. 11.97% of the stock is owned by institutional investors and hedge funds.

Gain Therapeutics Stock Performance

Shares of Gain Therapeutics stock opened at $1.75 on Wednesday. The stock has a market capitalization of $76.38 million, a price-to-earnings ratio of -3.50 and a beta of 0.20. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.36 and a quick ratio of 4.36. The business has a 50-day moving average of $1.83 and a 200 day moving average of $1.94. Gain Therapeutics has a 12 month low of $1.53 and a 12 month high of $4.34.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. As a group, sell-side analysts forecast that Gain Therapeutics will post -0.5 earnings per share for the current year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.